Search

Displaying results 3791 - 3800 of 10000 in total
  1. Drug

    Zatebradine

    go.drugbank.com/drugs/DB21228
    Experimental

    Zatebradine is a small molecule drug. The usage of the INN stem '-bradine' in the name indicates that Zatebradine is a bradycardic agent. Zatebradine has a monoisotopic molecular weight of 456.26 Da.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Dextropropoxyphene

    go.drugbank.com/drugs/DB00647
    ApprovedIllicitWithdrawn

    Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. … Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States.

    Mixtures: Darvocet-N 50, Darvocet-N 100Products: Darvon-N
  3. Drug

    Muraglitazar

    go.drugbank.com/drugs/DB06510
    Investigational

    in LDL-C levels. … In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment is associated with a substantial reduction in triglycerides (TGs), an increase in HDL-C, and a modest decrease

  4. Drug

    Imidafenacin

    go.drugbank.com/drugs/DB09262
    Investigational

    Imidafenacin is an antispasmodic agent with anticholinergic effects. It antagonizes muscarinic receptors in the bladder to reduce the frequency of urination in the treatment of overactive bladder. … It is marketed in Japan under the tradenames Staybla by Ono Pharmaceutical and Uritos by Kyojin Pharmaceutical.

  5. Drug

    Flubendazole

    go.drugbank.com/drugs/DB08974
    ApprovedInvestigationalWithdrawn

    Flubendazole is an anthelmintic that is used to treat worm infection in humans. It is available OTC in Europe.

  6. Drug

    Sovateltide

    go.drugbank.com/drugs/DB06138
    Investigational

    SPI-1620 is an endothelin B receptor agonist. In animal models SPI-1620 selectively and transiently increases tumor blood flow allowing increased delivery of anticancer agents to the tumor. … It is being developed as an adjunct to chemotherapy.

  7. Drug

    Aleglitazar

    go.drugbank.com/drugs/DB08915
    Investigational

    In the phase II clinical trial called SYNCHRONY, with type II diabetic patients, aleglitazar was able to control both lipid and glucose levels in a synergistic manner while also having limited side effects … Aleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO.

  8. Drug

    Eszopiclone

    go.drugbank.com/drugs/DB00402
    ApprovedInvestigational

    This sets it apart from many other hypnotic sedatives, which are generally approved only for the relief of short-term (6-8 weeks) insomnia. Eszopiclone was initially approved by the FDA in 2004. … One major benefit of eszopiclone is that it is approved by the FDA for the long-term treatment of insomnia.

  9. Drug

    Tolazoline

    go.drugbank.com/drugs/DB00797
    ApprovedVet approvedWithdrawn

    It is used in treatment of persistent pulmonary hypertension of the newborn. … A vasodilator that apparently has direct actions on blood vessels and also increases cardiac output.

  10. Drug

    Arsanilic acid

    go.drugbank.com/drugs/DB03006
    ExperimentalVet approved

    An arsenical which has been used as a feed additive for enteric conditions in pigs and poultry. It causes blindness and is ototoxic and nephrotoxic in animals. [PubChem]

    Categories: Compounds used in a research, industrial, or household setting